Products with Anti-obesity bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3817 | Glucoraphanin |
| 1. Glucoraphanin, the bioprecursor of the widely extolled chemopreventive agent sulforaphane found in broccoli, induces phase-I xenobiotic metabolizing enzymes and increases free radical generation in rat liver. 2. Glucoraphanin can ameliorates obesity and insulin resistance through adipose tissue browning and reduction of metabolic endotoxemia in mice. 3. Glucoraphanin and Glucoerucin effectively act as antagonists for the aryl hydrocarbon receptor, and this may contribute to their established chemoprevention potency. 4. Glucoraphanin has antioxidant activity, it has important effects on the reversion of fatty liver. | |
| BCN3996 | 2',4',6'-Trihydroxyacetophenone |
| 2',4',6'-Trihydroxyacetophenone has antiobesity and hypolipidemic effects, may be partly mediated by delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity. | |
| BCN4303 | Obacunone |
| Obacunone is a novel activator of Nrf2, which exhibits anti-cancer, anti-inflammatory, antivirulence, insecticidal, anti-proliferative and anti-aromatase activities. Obacunone stimulates muscle hypertrophy and prevents obesity and hyperglycemia, and that these beneficial effects are likely to be mediated through the activation of TGR5 and inhibition of PPARγ transcriptional activity. Obacunone significantly inhibits aromatase activity in an in vitro enzyme assay with an IC50 value of 28.04 μM, and it also inhibits the p38 MAPK signaling pathway. | |
| BCN4805 | 6,8-Diprenylgenistein |
| 1. 6,8-Diprenylgenistein has antimicrobial activity . 2. 6,8-Diprenylgenistein has anti-bacteria activity against Gram-negative and Gram-positive bacteria. | |
| BCN4876 | Lucidone |
| 1. Lucidone has anti-inflammatory activity, the activity might be caused by the inhibition of iNOS and COX-2 expressions through downregulation of NF-kappaB and AP-1 binding. 2. Lucidone has hepatoprotective effect, it-mediated up-regulation of phase-II enzymes and HO-1 via Nrf-2 signaling pathway may provide a pivotal mechanism for its hepatoprotective action. 3. Lucidone may possess antioxidant and anti-inflammatory properties and may be useful for the prevention of free radical-induced skin damage. 4. Dietary intake of lucidone alleviates high fat diet-induced obesity in C57BL/6 mice and reveals the potential of lucidone as a nutraceutical to prevent obesity and consequent metabolic disorders. 5. Lucidone accelerates wound healing through the cooperation of keratinocyte/fibroblast/ ndothelial cell growth and migration and macrophage inflammation via PI3K/AKT, Wnt/β-catenin and NF-κB signaling cascade activation. 6. Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction, it could be a potential lead or supplement for the development of new anti-HCV agent in the future. | |
